Results 151 to 160 of about 52,343 (282)

How Clinical Pharmacology Can Support Clinical Trial Diversity and Inclusion

Clinical and Translational Science, Volume 18, Issue 9, September 2025.
ABSTRACT Enrolling diverse populations during early clinical trial development and planning for diversity plans could be challenging. In 2024, the Diversity and Inclusion Clinical Pharmacology Leadership Group Working Group (D&I CPLG WG) from The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) collaborated with ...
Michael Z. Liao, Aarti Sawant, Brian Corrigan, Sebastian Haertter, Yasuto Otsubo, Islam R. Younis, Sreeneeranj Kasichayanula, Rashmi Mehta   +7 more
wiley   +1 more source

Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome

, 1991
Barry Harris, John T. Carpenter, Robert B. Diasio   +2 more
openalex   +1 more source

Pharmacogenetics and pharmacogenomics [PDF]

, 2001
Munir Pirmohamed
openalex   +1 more source

Impact of PNPLA3 I148M on Drug‐Induced Hepatocellular Liver Injury: A Systematic Review and Meta‐Analysis

Liver International, Volume 45, Issue 9, September 2025.
ABSTRACT Background and Aims The role of the patatin‐like phospholipase domain‐containing protein 3 (PNPLA3)‐I148M variant in drug‐induced liver injury (DILI) remains unclear. This systematic review with meta‐analysis investigated whether carriage of PNPLA3 I148M may contribute to the development of hepatocellular DILI.
Alexandra Gatzios, Lorna Marchandise, Hannes Hagström, Jörn M. Schattenberg, Robim M. Rodrigues, Tamara Vanhaecke, Joost Boeckmans   +6 more
wiley   +1 more source

Initial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long-term care facility

Pharmacogenomics and Personalized Medicine, 2016
Juan-Sebastian Saldivar, David Taylor, Elaine A Sugarman, Ali Cullors, Jorge A Garces, Kahuku Oades, Joel Centeno AltheaDx, San Diego, CA, USA Abstract: The health care costs associated with prescription drugs are enormous, particularly in patients with ...
Saldivar JS, Taylor D, Sugarman EA, Cullors A, Garces JA, Oades K, Centeno J   +6 more
doaj  

Pharmacogenetics of stereoselective metabolism of mephenytoin concerning human liver P-450 human -2.

, 1990
Ryuichi Kato
openalex   +2 more sources

Pharmacogenetic Interactions Between β-Blocker Therapy and the Angiotensin-Converting Enzyme Deletion Polymorphism in Patients With Congestive Heart Failure [PDF]

, 2001
Dennis M. McNamara, Richard Holubkov, Karen Janosko, Amy Palmer, Jue J. Wang, Guy A. MacGowan, Srinivas Murali, Warren D. Rosenblum, Barry London, Arthur M. Feldman   +9 more
openalex   +1 more source

Development of pharmacogenetics and clinical pharmacology. From molecular level to clinical medicine and drug development. Clinical significance of phenotyping and genotyping.

, 1996
Frank J. Gonzalez
openalex   +2 more sources

Enabling Large-Scale Pharmacogenetic Studies by High-Throughput Mutation Detection and Genotyping Technologies [PDF]

, 2001
Michael Shi
openalex   +1 more source

Development of clinical pharmacology and pharmacogenetics. Development from molecular level to clinical medicine and drugs. Positioni of pharmacogenetics in drug development.

, 1996
Eiji Uchida
openalex   +2 more sources